5th Molecular Glue Drug Development Summit | Boston, MA | January 26-28, 2027

Memo

From Revolution Medicines' landmark FDA approval of RASONQUE™ to major discovery partnerships such as the up to $1.4 billion Novartis-Orionis collaboration, molecular glues continue to generate momentum across both clinical development and early-stage innovation. Combined with rapid advances in artificial intelligence, automation, structural biology, and induced proximity therapeutics, the field is entering a new era of discovery, unlocking previously inaccessible biology and expanding the potential of molecular glues across a growing range of disease areas.As investment, scientific understanding, and translational success accelerate, the 5th Molecular Glue Drug Development Summit serves as the industry's only dedicated forum bringing together the scientists and drug developers advancing molecular glue therapeutics from early discovery through translational and clinical development.URLs:Tickets: https://go.evvnt.com/3839729-2?pid=5569Brochure: https://go.evvnt.com/3839729-3?pid=5569Date and Time: On Tuesday January 26, 2027 at 8:30 am to Thursday January 28, 2027 at 4:45 pmVenue details: Hyatt Regency Boston Harbor, 101 Harborside Drive, Boston, Massachusetts, 02128, United StatesPrices:Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 4507.00,Drug Developer Pricing - Conference Only: USD 3149.00,Academic Pricing - Conference + Pre-Conference Workshop Day: USD 3907.00,Academic Pricing - Conference Only: USD 2749.00,Service Provider Pricing - Conference + Pre-Conference Workshop Day: USD 5397.00,Service Provider Pricing - Conference Only: USD 3999.00Speakers: Ajinkya Patil, Principal Scientist, Pfizer, Anita Bellail, Chief Executive Officer, HB Therapeutics Inc, Antonio Lepore, Senior Associate, Canaan Partners, Aseem Ansari, Chair of the Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Asghar Razavi, Director of Molecular Modeling and Design, Fathom Therapeutics, Bret Williams, Senior VP, Research, Magnet Biomedicine, Charlie Hao, Chief Scientific Officer, Degron Therapeutics, Cheng Hu, Co-Founder and Chief Executive Officer, Technetium Therapeutics, Corey Strickland, Vice President of Molecular Technology, SK Life Science Labs, Emanuela Cuomo, Executive Director, Global Head of Discovery Pharmacology, Merck, Evris Gavathiotis, Professor of Biochemistry, Medicine, and Oncology, Albert Einstein College of Medicine, Felix Gonzalez, Scientific Director, Bristol Myers Squibb, Gali Prag, Co-Founder and Board Member, Coltac Therapeutics, Jeanine Harrigan, Vice President, Head of Biology, TernaryTx, Jonathan Solomon, Associate Director, Novartis AG, Masaya Yamaguchi, Principal Scientist, Pfizer, Mat Sowa, Vice President, Lead Discovery, C4 Therapeutics Inc, Meizhong Jin, Senior Director of Oncology Chemistry, AstraZeneca, Paul Lang, In Vitro Biology, Integrated Drug Discovery Head (US), Sanofi, Philip Komarnitsky, Chief Medical Officer, Nested Therapeutics, Riccardo Sabatini, Chief Data Scientist, Orionis Biosciences LLC, Rick Ewing, Vice President and Head of Chemistry, Rapafusyn, Ryan Richards, Associate Principal Scientist, AstraZeneca, Scott Edmondson, Senior Vice President, Chemistry, Nimbus Therapeutics, Xiulei Mo, Associate Professor, Emory University, Yuhong Du, Associate Professor, Emory University